Pharnext SAS Revenue and Competitors

Paris, FRA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pharnext SAS's estimated annual revenue is currently $4M per year.(i)
  • Pharnext SAS's estimated revenue per employee is $155,000

Employee Data

  • Pharnext SAS has 26 Employees.(i)
  • Pharnext SAS grew their employee count by -33% last year.

Pharnext SAS's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13M844%N/AN/A
#2
$23.9M154-1%N/AN/A
#3
$44.2M28522%N/AN/A
#4
$24M155-17%N/AN/A
#5
$17.4M1120%$179.5MN/A
#6
$49.4M2391%€201.1MN/A
#7
$54.3M350-3%N/AN/A
#8
$9.3M60N/AN/AN/A
#9
$7.8M50N/AN/AN/A
#10
$20.9M135-16%N/AN/A
Add Company

What Is Pharnext SAS?

Pharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPYâ„¢. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUGâ„¢ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com

keywords:N/A

N/A

Total Funding

26

Number of Employees

$4M

Revenue (est)

-33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M2630%N/A
#2
$3.7M26-75%N/A
#3
$2.6M26-30%N/A
#4
$2.5M26-21%N/A
#5
$4.6M26-4%N/A